You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Grassroots efforts are leading the way in a number of commercial and non-commercial screening tests in development.
New England Biolabs is using Avacta's affimers with a development-stage research and diagnostic assay that could launch as early as next year.
The services will couple NEB's reagents and expertise in enzyme development and manufacturing with TTP's Desktop Biology product development and engineering know-how.
